Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
Foghorn Therapeutics Inc. (FHTX)
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Anna Rivkin, Ph.D., will join the company as Chief Business Officer (CBO), on September 3, 2024. Dr. Rivkin brings over two decades of expertise in a broad spectrum of complex business transactions across multiple disease areas. “We have significant potential in our pipeline and platform as we continue to build Foghorn," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. “During this exciting stage of growth, we are delighted to welcome Anna as our Chief Business Officer. Anna brings significant industry experience in establishing strategic alliances, R&D partnerships, in-licensing and M&A which will position us for success in our future business development efforts.” Before joining Foghorn, Anna mo
Show less
Read more
Impact Snapshot
Event Time:
FHTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FHTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FHTX alerts
High impacting Foghorn Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
FHTX
News
- Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech IndustryPR Newswire
- Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its price target raised by analysts at Morgan Stanley from $6.00 to $9.00. They now have an "equal weight" rating on the stock.MarketBeat
- Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength? [Yahoo! Finance]Yahoo! Finance
- Foghorn Therapeutics Inc. (NASDAQ: FHTX) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $18.00 price target on the stock.MarketBeat
- Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in SeptemberGlobeNewswire
FHTX
Earnings
- 8/8/24 - Beat
FHTX
Sec Filings
- 9/24/24 - Form 4
- 9/20/24 - Form SC
- 9/20/24 - Form 4
- FHTX's page on the SEC website